Celastrol / TumCP Cancer Research Results

Cela, Celastrol: Click to Expand ⟱
Features:

Celastrol — a quinone methide pentacyclic triterpenoid natural product isolated mainly from Tripterygium wilfordii and related Celastraceae plants. It is best classified as a pleiotropic redox-reactive small molecule with proteostasis-disrupting, anti-inflammatory, and anticancer activity. Standard abbreviations include Cel and CeT. In oncology, celastrol is best viewed as a preclinical multi-target stress inducer rather than a selective single-node inhibitor, with recurring emphasis on thiol-reactive proteostasis disruption, NF-κB suppression, ROS-linked mitochondrial injury, and context-dependent inhibition of STAT3 and PI3K/AKT signaling. Clinically important caveats are poor water solubility, poor oral bioavailability, rapid disposition, and a narrow therapeutic window that has driven strong interest in nanoformulations and conjugates.

Primary mechanisms (ranked):

  1. Proteostasis disruption with functional HSP90 inhibition and heat-shock response activation
  2. NF-κB pathway suppression through inhibition of pro-survival inflammatory signaling
  3. ROS elevation with mitochondrial dysfunction and intrinsic apoptosis
  4. JAK2/STAT3 axis inhibition in responsive tumor contexts
  5. Secondary down-modulation of PI3K/AKT/mTOR and related growth-survival signaling
  6. Context-dependent suppression of invasion, angiogenesis, and metastatic programs including CXCR4 and HIF-1-related outputs
  7. Chemosensitization and stress-vulnerability amplification in selected resistant tumor models

Bioavailability / PK relevance: Celastrol is practically insoluble or very poorly soluble in water, has poor oral bioavailability, and shows dose-limiting systemic toxicity; delivery systems are commonly used to improve exposure and reduce off-target injury.

In-vitro vs systemic exposure relevance: Many mechanistic and cytotoxicity studies use low-micromolar concentrations that are difficult to reproduce safely with conventional systemic dosing. Some pathway effects may still occur at lower exposures, but direct tumoricidal effects are often concentration-limited without advanced formulations.

Clinical evidence status: Strong preclinical oncology signal; early translational and formulation work; no approved cancer indication. Human clinical registration appears limited to non-oncology safety/other exploratory studies rather than established anticancer efficacy trials. *** Appears more useful used at lower doses in combined treatment approaches.

Celastrol—a bioactive compound extracted from traditional Chinese medicinal plants such as Tripterygium wilfordii (Thunder God Vine).

Pathways:
-inhibit NF-κB activation
-disrupt the function of chaperone proteins like HSP90 and HSP70, which are often overexpressed in cancer cells
-attenuate Akt phosphorylation and downstream mTOR signaling
-modulate components of the MAPK pathway, including ERK, JNK, and p38.
-increase intracellular ROS levels in cancer cells
-inhibiting STAT3

Celastrol mechanistic map in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 HSP90 proteostasis disruption ↓ client protein stability; ↑ heat-shock stress ↑ stress response (dose-dependent) P/R Destabilization of oncogenic signaling networks Mechanistically central and industry-relevant. Celastrol behaves as a thiol-reactive disruptor of chaperone-dependent proteostasis rather than a highly selective kinase inhibitor.
2 NF-κB inflammatory survival signaling ↓ ↓ inflammatory tone R/G Reduced survival, proliferation, cytokine signaling, and invasion One of the most reproducible anticancer themes; also helps explain anti-inflammatory overlap outside oncology.
3 Mitochondrial ROS increase ↑ (primary; dose-dependent) ↑ (high concentration only) P/R Oxidative stress overload and stress sensitization The quinone methide scaffold is redox-reactive. ROS often acts upstream of mitochondrial depolarization, apoptosis, and therapy sensitization.
4 Mitochondria and intrinsic apoptosis MMP ↓; Bax/Bcl-2 balance toward apoptosis; caspases ↑ ↑ injury at higher exposure R/G Apoptotic tumor cell death Usually linked to ROS and proteotoxic stress rather than an isolated primary target.
5 JAK2 STAT3 signaling ↓ (context-dependent) ↔ R/G Reduced proliferation, survival, and inflammatory transcription Supported in multiple tumor models, including myeloma and more recent metastatic-cancer work, but not necessarily dominant in every model.
6 PI3K AKT mTOR axis ↓ (secondary) ↔ / ↓ R/G Anabolic and survival suppression Often appears downstream of broader stress and chaperone disruption.
7 Invasion metastasis and angiogenesis programs CXCR4 ↓; motility ↓; VEGF signaling ↓; HIF-1α ↔ (context-dependent) ↔ G Reduced metastatic competence and tumor vascular support HIF-1-related effects are mixed across sources and models; anti-invasive and anti-angiogenic effects are better supported than a uniform HIF-1α direction.
8 NRF2 antioxidant response ↑ adaptive defense or overwhelm (context-dependent) ↑ cytoprotective stress response R/G Bidirectional redox adaptation Relevant, but not a clean core anticancer mechanism. NRF2 activation can be protective in normal tissue yet may also buffer tumor oxidative stress in some settings.
9 Chemosensitization ↑ therapy response ↔ / toxicity risk G Overcoming resistance in selected models Supported especially where NF-κB/STAT3-dependent resistance is prominent; still largely preclinical.
10 Clinical Translation Constraint Exposure limited Toxicity limited — Narrow therapeutic window Poor solubility, poor oral bioavailability, rapid metabolism/disposition, and organ-toxicity risk are major barriers to systemic oncology use.

TSF legend:
P: 0–30 min (direct redox/protein interactions)
R: 30 min–3 hr (acute stress and signaling shifts)
G: >3 hr (gene regulation and phenotype outcomes)
TumCP, Tumor Cell proliferation: Click to Expand ⟱
Source:
Type:
Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors.
Scientific Papers found: Click to Expand⟱
5944- Cela,    HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
- in-vitro, AML, U937
TumCP↓, TumCCA↑, TumCD↑, HSP90↓, HSP70/HSPA5↑, cycD1/CCND1↓, CDK4↓, CDK6↓, ATPase↓,
5953- Cela,  CUR,    The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis
- vitro+vivo, NPC, NA
eff↑, TumCP↓, GPx4↓, eff↑, TumAuto↑, Ferroptosis↑, Dose↝, ACSL4↑, toxicity↓,
5948- Cela,    Recent Trends in anti-tumor mechanisms and molecular targets of celastrol
TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumMeta↓, Imm↝, angioG↓, Cyt‑c↑, ROS↑, BAX↑, Casp3↑, Casp9↑, cl‑PARP↑, PrxII↓, ER Stress↑, mtDam↑, CHOP↑, Inflam↓, NF-kB↓, CXCR4↓, MMP9↓, IL6↓, TNF-α↓, HSP90↓, neuroP↑, STAT3↓, Prx↓, HO-1↑, eff↑, eff↑, BioAv↑, toxicity↑, CardioT↑, hepatoP↓,
5942- Cela,    Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer
- vitro+vivo, NSCLC, H460 - in-vitro, NSCLC, PC9
TumCG↓, TumCP↓, TumMeta↓, ROS↑, ER Stress↑, p‑STAT3↓, Apoptosis↑, eff↓, TumCG↓, IL6↓, other↝,
5940- Cela,    Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway
- in-vivo, Pca, PC3
Dose↝, TumVol↓, TumW↓, angioG↓, VEGF↓, TumCMig↓, TumCP↓, TumCI↓, Akt↓, mTOR↓, P70S6K↓,
5939- Cela,  Chemo,    Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells
- in-vitro, Melanoma, U266 - in-vitro, Melanoma, RPMI-8226
TumCP↓, ChemoSen↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, XIAP↓, Mcl-1↓, NF-kB↓, IL6↓, STAT3↓, Apoptosis↑, TumCCA↑, Casp3↑, HSP90↓, HO-1↑, JAK2↓, Src↓, Akt↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   HO-1↑, 2,   Prx↓, 1,   PrxII↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   Mcl-1↓, 1,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 2,   HSP70/HSPA5↑, 1,   HSP90↓, 3,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 2,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,   P70S6K↓, 1,   Src↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 2,  

Migration ⓘ

ATPase↓, 1,   MMP9↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 6,   TumMeta↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL6↓, 3,   Imm↝, 1,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 2,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   Dose↝, 2,   eff↓, 1,   eff↑, 4,  

Clinical Biomarkers ⓘ

IL6↓, 3,  

Functional Outcomes ⓘ

CardioT↑, 1,   hepatoP↓, 1,   neuroP↑, 1,   toxicity↓, 1,   toxicity↑, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 66

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumCP, Tumor Cell proliferation
6 Celastrol
1 Curcumin
1 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:317  Target#:327  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page